Abstracts Archive - Page 1099 of 2425 - ACR Meeting Abstracts

Abstract Number: 1416 • 2018 ACR/ARHP Annual Meeting
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Simone Carbogno¹, Denise Pires Marafon², Giulia Marucci³, Manuela Pardeo³, Antonella Insalaco³, Virginia Messia³, Rebecca Nicolai³, Fabrizio De Benedetti⁴ and Claudia Bracaglia³, ¹University of Milan, Milan, Italy, ²Pediatric Unit, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…
Abstract Number: 1417 • 2018 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Giulia Marucci¹, Ivan Caiello², Manuela Pardeo¹, Virginia Messia¹, Giusi Prencipe¹, Antonia Pascarella¹, Fabrizio De Benedetti³ and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2),…
Abstract Number: 1418 • 2018 ACR/ARHP Annual Meeting
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Isabelle Koné-Paut¹, Maryam Piram², Susanne Benseler³, Jasmin B. Kuemmerle-Deschner⁴, Annette F. Jansson⁵, Itzhak Rosner⁶, Alberto Tommasini⁷, Sara Murias⁸, Omer Karadag⁹, Jeremy Levy¹⁰, Serge Smeets¹¹ and Fabrizio De Benedetti¹², ¹APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ²Pediatrics, APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University Hospital Tübingen, Tübingen, Germany, ⁵Ludwig Maximilian University, Munich, Germany, ⁶Bnai-Zion Medical Center, Haifa, Israel, ⁷Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ¹⁰BIOP, Reinach, AR, Switzerland, ¹¹Novartis Pharma B.V., Arnhem, Netherlands, ¹²IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
Giorgia Martini¹, Gloria Fadanelli¹, Anna Agazzi¹, Fabio Vittadello¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…
Abstract Number: 1420 • 2018 ACR/ARHP Annual Meeting
Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
Alessandra Meneghel¹, Stefano Puggina², Eleni Kamburi³, Giorgia Martini³, Fabio Vittadello³ and Francesco Zulian¹, ¹University of Padua, Department of Woman and Child Health, Padua, Italy, ²Unix Radiology Service, Affidea Group, Piove di Sacco, Italy, ³Department of Woman and Child Health, University of Padua, Padua, Italy
Background/Purpose: Currently, the techniques used for the monitoring of Localized Scleroderma of the face (LSF) have significant limitations. We prospectively evaluated the reliability of the…
Abstract Number: 1421 • 2018 ACR/ARHP Annual Meeting
Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis
Oya Koker¹, Amra Adrovic², Sezgin Sahin², Kenan Barut², Rukiye Omeroglu³ and Ozgur Kasapcopur⁴, ¹Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ³Pediatric Rheumatology, Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Pulmonary vascular disease and interstitial lung fibrosis are the leading causes of morbidity and mortality in Juvenile Systemic Sclerosis (JSSc). Six-minute walk test (6MWT)…
Abstract Number: 1422 • 2018 ACR/ARHP Annual Meeting
Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life
Vidya Sivaraman¹, Kathryn S. Torok², Melissa Moore-Clingenpeel³, Fatma Dedeoglu⁴, Polly Ferguson⁵, Elena Pope⁶, Thomas G. Mason II⁷, Mara L Becker⁸, Gloria Higgins⁹, C. Egla Rabinovich¹⁰, Sandy Hong¹¹, Maria Ibarra¹², Ronald M. Laxer¹³, Robert Fuhlbrigge¹⁴, Katie Stewart¹⁵, Marilynn Punaro¹⁶ and Suzanne Li¹⁷, ¹Nationwide Children’s Hospital and The Ohio State University, Columbus, OH, ²Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ³Research, Nationwide Children's Hospital, Dublin, OH, ⁴Rheumatology, Boston Children's Hospital, Boston, MA, ⁵Pediatrics, University of Iowa, Iowa City, IA, ⁶Section of Dermatology, The Hospital for Sick Children, Hospital for Sick Children, Toronto, ON, Canada, ⁷Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, ⁸Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁹Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ¹⁰Duke University Medical Center, Durham, NJ, ¹¹Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ¹²Children's Mercy Hospital, Kansas City, MO, Kansas City, MO, ¹³Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Children's Hospital Colorado, Aurora, CO, ¹⁵UT Southwestern, Dallas, TX, ¹⁶Texas Scottish Rite Hospital for Children, Dallas, TX, ¹⁷Pediatrics, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic autoimmune disease, with cutaneous and extra-cutaneous manifestations (ECM) requiring long-term immunosuppressive therapy. Few studies have evaluated the…
Abstract Number: 1423 • 2018 ACR/ARHP Annual Meeting
Autoantibody Testing in Pediatric Localized Scleroderma (LS)
Aidan Porter¹, Emily Mirizio², Marvin J. Fritzler³, Rachael Brown⁴, May Choi³, Kaila Schollaert-Fitch⁵, Christopher Liu⁵ and Kathryn S. Torok⁶, ¹Peds, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA, ³Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁶Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is typically categorized by the depth and extent of skin lesions into main subtypes: linear scleroderma, including linear trunk/limb and…
Abstract Number: 1424 • 2018 ACR/ARHP Annual Meeting
After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Maria Teresa Terreri⁴, Tadey Avcin⁵, Rolando Cimaz⁶, Mikhail Kostik⁷, Maria M. Katsicas⁸, Dana Nemkova⁹, Cristina Battagliotti¹⁰, Lillemor Berntson¹¹, Juergen Brunner¹², Liora Harel¹³, Tilmann Kallinich¹⁴, Kirsten Minden¹⁵, Maria José Santos¹⁶, Kathryn S. Torok¹⁷ and Nicola Helmus¹, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁴Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ⁵University Children's Hospital, Ljubljana, Slovenia, ⁶Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ⁷Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation, ⁸Service of Immunology & Rheumatology., Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ⁹Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁰Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ¹¹Dept. of Pediatrics, Uppsala University Hospital, Uppsala, Sweden, ¹²Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, ¹³Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹⁴Charité Berlin Campus Virchow, Berlin, Germany, ¹⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ¹⁶Reuma.pt, Almada, Portugal, Almada, Portugal, ¹⁷Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence 3 in a 1 000 000 children(1). Published data is limited regarding the…
Abstract Number: 1425 • 2018 ACR/ARHP Annual Meeting
Update from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn S. Torok⁵, Valda Stanevicha⁶, Flavio Sztajnbok⁷, Maria Teresa Terreri⁸, Ekaterina Alexeeva⁹, Jordi Anton¹⁰, Maria M. Katsicas¹¹, Vanessa Smith¹², Tadey Avcin¹³, Rolando Cimaz¹⁴, Mikhail Kostik¹⁵, Thomas J. A. Lehman¹⁶, Walter A. Sifuentes-Giraldo¹⁷, Simone Appenzeller¹⁸, Mahesh Janarthanan¹⁹, Dana Nemkova²⁰, Maria José Santos²¹, Cristina Battagliotti²², Lillemor Berntson²³, Blanca Bica²⁴, Juergen Brunner²⁵, Patrícia Costa Reis²⁶, Despina Eleftheriou²⁷, Liora Harel²⁸, Gerd Horneff²⁹, Tilmann Kallinich³⁰, Dragana Lazarevic³¹, Kirsten Minden³², Susan Mary Nielsen³³, Yosef Uziel³⁴ and Nicola Helmus¹, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁴Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, ⁵Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁶Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ⁷Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁸Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ⁹National Medical Research Center of Children's Health and Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ¹⁰Hospital Sant Joan de Deu, Barcelona, Spain, ¹¹Service of Immunology & Rheumatology., Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ¹²Department of Internal Medicine, Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium, ¹³University Children's Hospital, Ljubljana, Slovenia, ¹⁴Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁵Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation, ¹⁶Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ¹⁷Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Faculty of Medical Science State University of Campinas (UNICAMP), Sao Paulo, Brazil, ¹⁹Pediatric Rheumatology, Chennai, India, ²⁰Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ²¹Reuma.pt, Almada, Portugal, Almada, Portugal, ²²Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ²³Dept. of Pediatrics, Uppsala University Hospital, Uppsala, Sweden, ²⁴"Chefe do Serviço de Reumatologia do Hospital Universitário Clementino Fraga Filho (HUCFF)Universidade Federal do Rio de Janeiro ", Rio de Janeiro, Brazil, ²⁵Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, ²⁶Pediatrics, Hospital De Santa Maria, Lisbon, Portugal, ²⁷Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²⁸Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ²⁹Asklepios Kinderklinik St. Augustin GmbH, Sankt Augustin, Germany, ³⁰Charité Berlin Campus Virchow, Berlin, Germany, ³¹Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Nis, Serbia, ³²Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ³³Rigshospitalet, Copenhagen, Denmark, ³⁴Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children(1). There is limited data published regarding…
Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Najla Aljaberi¹, Angela Merritt², Alexei Grom¹, Grant Schulert³, Jennifer L. Huggins⁴, Michael Henrickson⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children’s Medical Center, Cincinnati, OH
Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
Abstract Number: 1427 • 2018 ACR/ARHP Annual Meeting
A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care
Roberta Berard¹, Susan MacQueen², Michelle Diebold³, Y. Ingrid Goh⁴, Anne MacLeod⁵, Kristi Whitney-Mahoney⁶, Christine O'Brien⁶, Brian M. Feldman⁷ and Deborah M. Levy⁸, ¹Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ²The Arthritis Society, Kitchener, ON, Canada, ³Department of Rheumatology, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁴Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Arthritis Society, Thunder Bay, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
AbstractBackground/Purpose: Twenty-five pediatric rheumatologists (PR) service a population of 14 million Ontarians. To facilitate care to patients living in distance communities we proposed a new…
Abstract Number: 1428 • 2018 ACR/ARHP Annual Meeting
Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases
Pauline Yi¹, Hana Conlon², Jae Hee Yun³, Kayla Neville², George Danias², Anca Askanase⁴ and Lisa F. Imundo⁵, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, New York, NY, ³Medicine/Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Pediatrics, Columbia University Medical Center, New York, NY
Background/Purpose: A NIH focus group study found that adolescents and young adults (AYA) with active disease relied heavily on their parents for disease management. It…
Abstract Number: 1429 • 2018 ACR/ARHP Annual Meeting
A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
Kimberly DeQuattro¹, Michael Evans¹, Aimee O. Hersh², Jinoos Yazdany¹, Emily von Scheven³ and Erica Lawson³, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ³Pediatrics/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Transfer from pediatric- to adult-oriented health care is challenging for patients with childhood-onset rheumatologic disease, and may be associated with treatment non-adherence, disease flares…
Abstract Number: 1430 • 2018 ACR/ARHP Annual Meeting
Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
Tamar Rubinstein¹, Lindsay Waqar², Jennifer Woo³, Ekemini Ogbu⁴, W. Blaine Lapin⁵, Lawrence Ng⁶, Erin Treemarcki⁷ and Andrea M. Knight⁸, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of California Los Angeles, Los Angeles, CA, ⁴Pediatrics, Emory University, Atlanta, GA, ⁵Baylor College of Medicine, Houston, TX, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁸Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Mental health problems are prevalent in pediatric rheumatology patients. Gaps in knowledge exist regarding the detection, effective treatment, and the impact of mental illness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].